argenx to Present at Upcoming Investor Conferences
03 Septembre 2021 - 7:00AM
September 3, 2021Breda, the
Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced that members of management will participate in several
upcoming conferences:
- KBC Life Sciences & Biotech
Virtual Conference. Management will participate in investor
meetings on Tuesday, September 7, 2021.
- Morgan Stanley Global Healthcare
Conference. Fireside chat on Friday, September 10, 2021 at 4:15
p.m. ET.
- BofA Global Healthcare Conference.
Fireside chat on Thursday, September 16, 2021 at 4:45 p.m.
BST.
- SVB Leerink CybeRx Series:
Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event.
Management will participate in investor meetings on Wednesday,
September 22, 2021.
Additional information regarding these events
will be available on the Investors section of the argenx website at
argenx.com/investors.
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases and cancer. Partnering with leading academic researchers
through its Immunology Innovation Program (IIP), argenx aims to
translate immunology breakthroughs into a world-class portfolio of
novel antibody-based medicines. argenx is evaluating efgartigimod
in multiple serious autoimmune diseases. argenx is also advancing
several earlier stage experimental medicines within its therapeutic
franchises. argenx has offices in Belgium, the United States,
Japan, and Switzerland. For more information, visit www.argenx.com
and follow us on LinkedIn.
For further information, please
contact:
Media:Kelsey
Kirkkkirk@argenx.com
Joke Comijn (EU)jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024